Three Strikes, But Not Out Yet, Lilly’s Donanemab Approval Delayed Again
Accelerated Approval Snub Was More Than A Year Ago
The US FDA wants to hold an advisory committee meeting for Lilly’s donanemab in early Alzheimer’s disease, which means approval will now occur after the expected Q1 decision date.
